### Dr. Daniel Griffin's Clinical treatment summary for 12/15/2022

## <u>Clinical Course/Treatment – Polio</u>

#### **Polio Vaccine**

Adults who are unvaccinated or without any documentation of previous polio vaccination should be given three doses of IPV at these recommended intervals:

- 1. Two doses separated by 1 to 2 months
- 2. A third dose 6 to 12 months after the second dose

### Clinical Course/Treatment - Monkeypox

**MPX CLINCIAL COURSE/TREATMENT:** Observation or in some cases TPOXX or if eye involvement VIROPTIC eye drops (trifluridine)

#### **VACCINATION:**

People who meet all of the following criteria are eligible to be vaccinated:

- Are a gay, bisexual, or other man who has sex with men and/or are transgender, gender non-conforming, or gender non-binary;
- Are age 18 or older, and;
- Have had multiple or anonymous sex partners in the last 14 days

### Clinical Course/Treatment - COVID

#### **PASSIVE VACCINATION**

Variants –now obsolete in much of our country

https://covid.cdc.gov/covid-data-tracker/#variant-proportions

#### **POST-EXPOSURE PERIOD**

https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html

COVID- Early Viral Upper Respiratory Non-hypoxic phase – <a href="https://www.covid.gov">https://www.covid.gov</a>

### Dr. Daniel Griffin's Clinical treatment summary for 12/15/2022

1-Paxlovid – https://www.fda.gov/media/155050/download

drug interaction checkers <a href="https://www.covid19-druginteractions.org/checker">https://www.covid19-druginteractions.org/checker</a> and <a href="https://www.idsociety.org/paxlovid">https://www.idsociety.org/paxlovid</a>

2 -Remdesivir -(approved for down to 28 days of age) 3-day early IV

https://www.vekluryhcp.com/?utm\_id=iw\_sa\_11453738585\_111635246813&utm\_medium=cpc&utm\_term=medicine+remdesivir&gclid=CjwKCAjwj42UBhAAEiwAClhADocodyE-OQCnF5PXs6x5nuFnH230Tc-4V3iFulmtEoxHgYAY1Tr7hhoCTOoQAvD\_BwE&gclsrc=aw.ds
https://files.constantcontact.com/17b067e5501/04046d2f-51dc-490f-89e1-edb5c535eeb6.pdf?rdr=true

3-Monoclonal Rx- waiting for a replacement

And now with the Variants <a href="https://covid.cdc.gov/covid-data-tracker/#variant-proportions">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>

4-Molnupiravir – last and least

30% reduction in progression so less impressive but no renal issues or drug interactions. Be careful w woman of childbearing age and get that negative pregnancy test, and NOT authorized for those under 18. https://www.nejm.org/doi/full/10.1056/NEJMoa2116044

https://onlinelibrary.wiley.com/doi/10.1002/jmv.28011

5-Avoid: let us not do harmful things

- 1. No steroids
- 2. No unnecessary antibiotics
- 3. Etc.

https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html#iso

https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html#

https://covid.cdc.gov/covid-data-tracker/#variant-proportions

https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

https://www.covid19treatmentguidelines.nih.gov/

https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1

- 1-Steroids at the right time in the right patient at the right dose. This is *after* the first week and in patients with oxygen saturations <94%. This gives us about a 17% mortality reduction <a href="https://www.nejm.org/doi/full/10.1056/nejmoa2021436">https://www.nejm.org/doi/full/10.1056/nejmoa2021436</a>
- 2-Anticoagulation Guidelines from a number of organizations including ASH <a href="https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19">https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19</a>

3-Pulmonary support.

# Dr. Daniel Griffin's Clinical treatment summary for 12/15/2022

4-Maybe Remdesivir if early, not if they are on a ventilator (first 10 days from symptom onset)

5-Immune modulation: Tocilizumab, the IL6-R blocker and in some cases Baricitinib, but only if there is progression and benefits outweigh risks.

6-AVOID: unnecessary antibiotics and unproven therapies